Ryo Iwamura

466 total citations
16 papers, 362 citations indexed

About

Ryo Iwamura is a scholar working on Ophthalmology, Public Health, Environmental and Occupational Health and Pharmacology. According to data from OpenAlex, Ryo Iwamura has authored 16 papers receiving a total of 362 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Ophthalmology, 5 papers in Public Health, Environmental and Occupational Health and 4 papers in Pharmacology. Recurrent topics in Ryo Iwamura's work include Glaucoma and retinal disorders (9 papers), Ocular Surface and Contact Lens (5 papers) and Inflammatory mediators and NSAID effects (4 papers). Ryo Iwamura is often cited by papers focused on Glaucoma and retinal disorders (9 papers), Ocular Surface and Contact Lens (5 papers) and Inflammatory mediators and NSAID effects (4 papers). Ryo Iwamura collaborates with scholars based in Japan, Germany and United States. Ryo Iwamura's co-authors include Kenji Yoneda, Naveed Shams, Noriko Odani‐Kawabata, Takazumi Taniguchi, Takeshi Matsugi, Fumitoshi Asai, Atsuhiro Sugidachi, Taketoshi Ogawa, Hiroyuki Koike and Ken‐ichi Otsuguro and has published in prestigious journals such as PLoS ONE, The FASEB Journal and Journal of Medicinal Chemistry.

In The Last Decade

Ryo Iwamura

16 papers receiving 350 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryo Iwamura Japan 8 202 105 82 71 68 16 362
R. A. Baroody United States 12 168 0.8× 63 0.6× 153 1.9× 13 0.2× 137 2.0× 15 411
Mitsunori Waki Japan 7 178 0.9× 21 0.2× 16 0.2× 4 0.1× 186 2.7× 8 390
L. Malvitte France 7 189 0.9× 78 0.7× 9 0.1× 7 0.1× 177 2.6× 12 468
Ronald J. Walkenbach United States 13 64 0.3× 53 0.5× 22 0.3× 14 0.2× 214 3.1× 27 389
Vladimir Mastyugin United States 8 49 0.2× 47 0.4× 86 1.0× 8 0.1× 172 2.5× 12 427
Dipak Kumar India 11 112 0.6× 30 0.3× 9 0.1× 3 0.0× 91 1.3× 25 343
Sara Vezzoli Italy 12 60 0.3× 6 0.1× 18 0.2× 8 0.1× 78 1.1× 18 318
Yoshinao Majima Japan 12 96 0.5× 31 0.3× 5 0.1× 5 0.1× 149 2.2× 30 357
Allyson L. Toro United States 13 95 0.5× 10 0.1× 8 0.1× 6 0.1× 235 3.5× 29 355
Ben Lane United States 9 17 0.1× 37 0.4× 54 0.7× 4 0.1× 111 1.6× 10 422

Countries citing papers authored by Ryo Iwamura

Since Specialization
Citations

This map shows the geographic impact of Ryo Iwamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryo Iwamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryo Iwamura more than expected).

Fields of papers citing papers by Ryo Iwamura

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryo Iwamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryo Iwamura. The network helps show where Ryo Iwamura may publish in the future.

Co-authorship network of co-authors of Ryo Iwamura

This figure shows the co-authorship network connecting the top 25 collaborators of Ryo Iwamura. A scholar is included among the top collaborators of Ryo Iwamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryo Iwamura. Ryo Iwamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Fuwa, Masahiro, et al.. (2023). Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells. PLoS ONE. 18(1). e0280331–e0280331. 4 indexed citations
2.
Fuwa, Masahiro, Atsushi Shimazaki, Noriko Odani‐Kawabata, et al.. (2021). Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys. Journal of Ocular Pharmacology and Therapeutics. 37(4). 223–229. 16 indexed citations
3.
Katsuta, Osamu, Takahisa Noto, Ryo Iwamura, et al.. (2020). The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice. Journal of Ocular Pharmacology and Therapeutics. 36(7). 529–533. 17 indexed citations
4.
Yamamoto, Yasuko, Takazumi Taniguchi, Tomoaki Inazumi, et al.. (2020). Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells. Journal of Ocular Pharmacology and Therapeutics. 36(3). 162–169. 30 indexed citations
5.
Sharif, Najam A., Ryo Iwamura, Kenji Yoneda, et al.. (2020). A Novel Non‐Prostaglandin EP2‐Receptor Agonist for Glaucoma Treatment: Omidenepag Isopropyl (DE‐117). The FASEB Journal. 34(S1). 1–1. 4 indexed citations
6.
Yamamoto, Yasuko, Takazumi Taniguchi, Masahiro Ota, et al.. (2019). Effects of Omidenepag, a Selective EP2 Receptor Agonist on Adipocyte Differentiation. Investigative Ophthalmology & Visual Science. 60(9). 3781–3781. 1 indexed citations
7.
Katsuta, Osamu, Takazumi Taniguchi, Ryo Iwamura, et al.. (2018). Effects of a selective EP2 receptor agonist, omidenepag isopropyl, on eyelash growth in mice. Investigative Ophthalmology & Visual Science. 59(9). 2718–2718. 1 indexed citations
8.
Fuwa, Masahiro, Carol B. Toris, Shan Fan, et al.. (2018). Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. Journal of Ocular Pharmacology and Therapeutics. 34(7). 531–537. 66 indexed citations
9.
Taniguchi, Takazumi, Kenzo Yamamura, Ryo Iwamura, et al.. (2018). Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent. Investigative Ophthalmology & Visual Science. 59(1). 145–145. 71 indexed citations
10.
Iwamura, Ryo, et al.. (2018). Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl. Journal of Medicinal Chemistry. 61(15). 6869–6891. 40 indexed citations
11.
Aihara, Makoto, Fenghe Lu, Yuki Tanaka, et al.. (2017). Pharmacokinetics, Safety and IOP Lowering Profiles of omidenepag isopropyl, a Selective EP2 Agonist in Healthy Japanese and Caucasian Volunteers (Phase I Study). Investigative Ophthalmology & Visual Science. 58(8). 2104–2104. 5 indexed citations
12.
Taniguchi, Takazumi, Miki Takahashi, Ryo Iwamura, et al.. (2017). Omidenepag isopropyl, a selective EP2 agonist, shows additive intraocular pressure (IOP)-lowering effects when used concomitantly with existing anti-glaucoma drugs in animal models. Investigative Ophthalmology & Visual Science. 58(8). 2105–2105. 1 indexed citations
13.
Iwamura, Ryo, et al.. (2015). DE-117, a selective EP2 agonist, lowered intraocular pressure in animal models. Investigative Ophthalmology & Visual Science. 56(7). 5709–5709. 6 indexed citations
14.
Lu, Fenghe, et al.. (2015). Safety and Efficacy of DE-117, a Selective EP2 Agonist in a Phase 2a Study. Investigative Ophthalmology & Visual Science. 56(7). 5708–5708. 9 indexed citations
15.
Sugidachi, Atsuhiro, Fumitoshi Asai, Kenji Yoneda, et al.. (2001). Antiplatelet action of R‐99224, an active metabolite of a novel thienopyridine‐type Gi‐linked P2T antagonist, CS‐747. British Journal of Pharmacology. 132(1). 47–54. 87 indexed citations
16.
Kazui, Miho, Naotoshi Yamamura, Haruo Iwabuchi, et al.. (2001). Mechanism for Production of Pharmacologically Active Metabolite of CS-747, A New Anti-Platelet Agent. Drug Metabolism and Pharmacokinetics. 16(supplement). 78–79. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. A. Baroody Breakdown of academic impact, for papers by Mitsunori Waki Breakdown of academic impact, for papers by L. Malvitte Breakdown of academic impact, for papers by Ronald J. Walkenbach Breakdown of academic impact, for papers by Vladimir Mastyugin Breakdown of academic impact, for papers by Dipak Kumar Breakdown of academic impact, for papers by Sara Vezzoli Breakdown of academic impact, for papers by Yoshinao Majima Breakdown of academic impact, for papers by Allyson L. Toro Breakdown of academic impact, for papers by Ben Lane
Rankless by CCL
2026